BiotechTube

Octreotide

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hypothalamic Obesity

Conditions

Hypothalamic Obesity

Trial Timeline

Feb 1, 2005 → —

NCT ID
NCT00171613

About Octreotide

Octreotide is a approved stage product being developed by Novartis for Hypothalamic Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT00171613. Target conditions include Hypothalamic Obesity.

What happened to similar drugs?

0 of 2 similar drugs in Hypothalamic Obesity were approved

Approved (0) Terminated (0) Active (2)
🔄Setmelanotide + PlaceboRhythm PharmaceuticalsPhase 3
🔄Setmelanotide + PlaceboRhythm PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT00332969Phase 2Completed
NCT00171613ApprovedCompleted
NCT00171886ApprovedCompleted
NCT00241020Phase 3Completed
NCT00521300ApprovedCompleted

Competing Products

7 competing products in Hypothalamic Obesity

See all competitors
ProductCompanyStageHype Score
MibavademabRegeneron PharmaceuticalsPhase 2
42
Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part B: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part C: RM-718 + Part D: RM-718Rhythm PharmaceuticalsPhase 1/2
36
Setmelanotide + PlaceboRhythm PharmaceuticalsPhase 3
41
Setmelanotide + PlaceboRhythm PharmaceuticalsPhase 3
44
SetmelanotideRhythm PharmaceuticalsPhase 2
32
BivamelagonRhythm PharmaceuticalsPhase 2
39
LB54640 + PlaceboRhythm PharmaceuticalsPhase 2
32